Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783642485> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2783642485 abstract "BACKGROUND Although sorafenib is accepted as the standard of care in advanced hepatocellular carcinoma (HCC), its therapeutic benefit is marginal. Here, we aimed to compare the efficacy and safety of sorafenib monotherapy (S-M) and sorafenib-based loco-regional treatments (S-LRTs) in advanced HCC. METHODS From 2007 to 2012, 290 patients with advanced HCC (Barcelona Clinic Liver Cancer stage C) with S-M (n = 226) or S-LRTs (n = 64) were reviewed retrospectively. Survival outcomes and treatment-related toxicities between two groups were analyzed. RESULTS Variables related to tumor burden and liver function were similar between the groups (all P > 0.05). Within the entire population, the S-LRTs group had both longer median overall survival (OS) (8.5 vs 5.5 months, P = 0.001) and progression-free survival (PFS) (5.3 vs 3.0 months, P = 0.002) than the S-M group. Furthermore, the S-LRTs group had longer Os than the S-M group in a subgroup with neither extrahepatic spread (EHS) nor regional nodal involvement (RNI) (18.0 vs 7.8 months, P = 0.019) and in a subgroup with EHS and/or RNI (8.3 vs 4.8 months, P = 0.028). In addition, the S-LRTs group had longer PFS than the S-M group in the subgroup with neither EHS nor RNI (9.6 vs 3.2 months, P = 0.027). TREATMENT Related toxicity was similar between two groups. CONCLUSION Combined use of sorafenib and LRTs may provide better treatment outcomes without significantly increasing treatment-related toxicities, even in patients with EHS and/or RNI. Therefore, addition of active LRTs might be considered, if feasible." @default.
- W2783642485 created "2018-01-26" @default.
- W2783642485 creator A5005948302 @default.
- W2783642485 creator A5025909748 @default.
- W2783642485 creator A5037059460 @default.
- W2783642485 creator A5040109906 @default.
- W2783642485 creator A5049575773 @default.
- W2783642485 creator A5054417741 @default.
- W2783642485 creator A5056295095 @default.
- W2783642485 creator A5064510358 @default.
- W2783642485 creator A5067263547 @default.
- W2783642485 date "2013-01-01" @default.
- W2783642485 modified "2023-10-18" @default.
- W2783642485 title "Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma" @default.
- W2783642485 hasPublicationYear "2013" @default.
- W2783642485 type Work @default.
- W2783642485 sameAs 2783642485 @default.
- W2783642485 citedByCount "0" @default.
- W2783642485 crossrefType "journal-article" @default.
- W2783642485 hasAuthorship W2783642485A5005948302 @default.
- W2783642485 hasAuthorship W2783642485A5025909748 @default.
- W2783642485 hasAuthorship W2783642485A5037059460 @default.
- W2783642485 hasAuthorship W2783642485A5040109906 @default.
- W2783642485 hasAuthorship W2783642485A5049575773 @default.
- W2783642485 hasAuthorship W2783642485A5054417741 @default.
- W2783642485 hasAuthorship W2783642485A5056295095 @default.
- W2783642485 hasAuthorship W2783642485A5064510358 @default.
- W2783642485 hasAuthorship W2783642485A5067263547 @default.
- W2783642485 hasConcept C126322002 @default.
- W2783642485 hasConcept C143998085 @default.
- W2783642485 hasConcept C187960798 @default.
- W2783642485 hasConcept C2776231280 @default.
- W2783642485 hasConcept C2778019345 @default.
- W2783642485 hasConcept C2778695046 @default.
- W2783642485 hasConcept C2908647359 @default.
- W2783642485 hasConcept C2992208098 @default.
- W2783642485 hasConcept C3019894029 @default.
- W2783642485 hasConcept C44249647 @default.
- W2783642485 hasConcept C71924100 @default.
- W2783642485 hasConcept C90924648 @default.
- W2783642485 hasConcept C99454951 @default.
- W2783642485 hasConceptScore W2783642485C126322002 @default.
- W2783642485 hasConceptScore W2783642485C143998085 @default.
- W2783642485 hasConceptScore W2783642485C187960798 @default.
- W2783642485 hasConceptScore W2783642485C2776231280 @default.
- W2783642485 hasConceptScore W2783642485C2778019345 @default.
- W2783642485 hasConceptScore W2783642485C2778695046 @default.
- W2783642485 hasConceptScore W2783642485C2908647359 @default.
- W2783642485 hasConceptScore W2783642485C2992208098 @default.
- W2783642485 hasConceptScore W2783642485C3019894029 @default.
- W2783642485 hasConceptScore W2783642485C44249647 @default.
- W2783642485 hasConceptScore W2783642485C71924100 @default.
- W2783642485 hasConceptScore W2783642485C90924648 @default.
- W2783642485 hasConceptScore W2783642485C99454951 @default.
- W2783642485 hasIssue "10" @default.
- W2783642485 hasOpenAccess W2783642485 @default.
- W2783642485 hasVolume "8" @default.
- W2783642485 isParatext "false" @default.
- W2783642485 isRetracted "false" @default.
- W2783642485 magId "2783642485" @default.
- W2783642485 workType "article" @default.